Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole Prophylaxis for GTN in Complete Hydatidiform Mole
NCT05203562Phase 3Unknown
- Sponsor
- Zagazig University
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole in gestational trophoblastic neoplasia (GTN) (2 arms), sponsored by Zagazig University. Primary endpoints: Beta-human chorionic gonadotropin level at 6 months and Incidence of Gestational Trophoblastic Neoplasia at 6 months. Status: unknown.
02
Drugs
letrozole
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT05203562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203562.